Johnson & Johnson (JNJ) to Acquire Firefly Bio for $1B

Johnson & Johnson (NYSE:JNJ) is one of the 7 Best Longevity Stocks to Buy Now.

On June 8, 2026, Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson & Johnson said the Firelink DAC platform bolsters its oncology pipeline and is designed to deliver a selective protein degrader to tumor cells while avoiding healthy cells. The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.

On June 3, 2026, Johnson & Johnson (NYSE:JNJ) announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjogren’s disease. The company said patients with elevated autoantibody and immunoglobulin G levels showed greater clinical response rates, with the findings supporting continued study of nipocalimab in the ongoing Phase 3 DAFFODIL study. Also on June 3, Johnson & Johnson said nipocalimab met the primary endpoint in the Phase 2 JASMINE study in adults with moderate-to-severe systemic lupus erythematosus, reducing disease activity at 24 weeks and showing sustained reduction through 52 weeks.

Johnson & Johnson (JNJ) to Acquire Firefly Bio for $1B

Trong Nguyen / Shutterstock.com

Johnson & Johnson also said the JASMINE study showed greater response versus placebo plus background medication in participants who tested positive for lupus-associated autoantibodies. At Week 52, 53.6% of patients receiving nipocalimab 15 mg/kg achieved an SRI-4 response, compared with 39.7% for placebo plus background medication. The company said nipocalimab had a safety profile consistent with previous studies, and no new safety signals were identified.

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures, and sells healthcare products worldwide.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1